Free tool
Drug Trial Radar: Endocrinology and women's health
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
8
Recruiting, industry sponsors, Endocrinology and women's health, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed188
8 trials
Showing 1 to 8, recently updated first.
- Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).Pivotal-lookingRecruiting
Tioga PharmaceuticalsIndustry
NCT07042516 · 120 participants (planned) · Start Aug 13, 2025 · Primary completion Oct 31, 2027
Drug: Asimadoline · For: Vasomotor Symptoms
Sites: Atlanta, Georgia
- Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)Pivotal-lookingRecruiting
Sparrow PharmaceuticalsIndustry
NCT07296484 · 1,500 participants (planned) · Start Nov 29, 2025 · Primary completion Dec 31, 2027
Drug: clofutriben; Placebo · For: Type 2 Diabetes; Cortisol Excess
Sites: Chandler, Arizona; Tucson, Arizona; Fountain Valley, California · 61 sites in all
- A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07264595 · 88 participants (planned) · Start Jan 18, 2026 · Primary completion Nov 2030
Drug: GS3-007a dry suspension; Placebo for GS3-007a dry suspension and 1 more · For: Pediatric Growth Hormone Deficiency
Sites: Wuhan, China
Marea TherapeuticsIndustry
NCT07641179 · 72 participants (planned) · Start Jul 23, 2026 · Primary completion Aug 2027
Drug: MAR002; Placebo · For: Acromegaly
Sites: Phoenix, Arizona; Columbus, Ohio; San Antonio, Texas
Xiamen Amoytop Biotech Co., Ltd.Industry
NCT07551804 · 36 participants (planned) · Start Jun 10, 2026 · Primary completion Dec 31, 2027
Drug: Inpegsomatropin Injection; Placebo for Inpegsomatropin Injection and 4 more · For: Adult Growth Hormone Deficiency
Sites: Beijing, China; Henan, China; Shanghai, China · 6 sites in all
- A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing RegimensPivotal-lookingRecruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07579936 · 200 participants (planned) · Start Apr 30, 2026 · Primary completion Jul 30, 2026
Drug: SAL056 56.5μg; Intervention Group 1 and 2 more · For: Postmenopausal Women With Osteoporosis
Sites: Beijing, China
RECORDATI GROUPIndustry
NCT03708900 · 12 participants (planned) · Start Apr 28, 2021 · Primary completion Jul 21, 2027
Drug: LCI699 · For: Cushing Syndrome
Sites: San Francisco, California; Cape Coral, Florida; Chicago, Illinois · 15 sites in all
- A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated PainPivotal-lookingRecruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT06963177 · 200 participants (planned) · Start May 26, 2025 · Primary completion May 15, 2028
Drug: GenSci048; Placebo · For: Endometriosis-related Pain
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.